8,072 Shares in Cencora, Inc. $COR Bought by Freedom Day Solutions LLC

Freedom Day Solutions LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 8,072 shares of the company’s stock, valued at approximately $2,424,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COR. Steph & Co. lifted its position in shares of Cencora by 23.5% in the first quarter. Steph & Co. now owns 168 shares of the company’s stock worth $53,000 after purchasing an additional 32 shares in the last quarter. Cornerstone Wealth Group LLC boosted its holdings in Cencora by 1.6% during the first quarter. Cornerstone Wealth Group LLC now owns 2,434 shares of the company’s stock worth $760,000 after purchasing an additional 38 shares during the last quarter. OLD National Bancorp IN grew its position in Cencora by 0.4% in the first quarter. OLD National Bancorp IN now owns 9,964 shares of the company’s stock valued at $3,130,000 after purchasing an additional 40 shares in the last quarter. Staley Capital Advisers Inc. grew its position in Cencora by 0.7% in the first quarter. Staley Capital Advisers Inc. now owns 6,127 shares of the company’s stock valued at $1,925,000 after purchasing an additional 40 shares in the last quarter. Finally, Elmwood Wealth Management Inc. grew its position in Cencora by 0.9% in the second quarter. Elmwood Wealth Management Inc. now owns 4,314 shares of the company’s stock valued at $1,221,000 after purchasing an additional 40 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on COR. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. UBS Group reduced their price objective on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings upgraded Cencora from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, October 6th. Argus lowered their target price on Cencora to $340.00 and set a “buy” rating on the stock in a research report on Tuesday, June 23rd. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $363.81.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.38% of the company’s stock.

Cencora Trading Down 0.2%

Shares of Cencora stock opened at $340.07 on Tuesday. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The stock has a market cap of $64.90 billion, a P/E ratio of 25.27, a P/E/G ratio of 1.75 and a beta of 0.58. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The business’s 50 day moving average is $320.70 and its 200-day moving average is $303.48.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, beating the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The company had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. During the same quarter in the prior year, the firm posted $4.00 EPS. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. Equities research analysts predict that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 14th. Cencora’s dividend payout ratio is 17.83%.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.